1. Home
  2. EQ vs MRM Comparison

EQ vs MRM Comparison

Compare EQ & MRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQ
  • MRM
  • Stock Information
  • Founded
  • EQ 2017
  • MRM 2000
  • Country
  • EQ United States
  • MRM Japan
  • Employees
  • EQ N/A
  • MRM N/A
  • Industry
  • EQ Biotechnology: Pharmaceutical Preparations
  • MRM Other Consumer Services
  • Sector
  • EQ Health Care
  • MRM Consumer Discretionary
  • Exchange
  • EQ Nasdaq
  • MRM Nasdaq
  • Market Cap
  • EQ 12.2M
  • MRM 10.7M
  • IPO Year
  • EQ 2018
  • MRM 2020
  • Fundamental
  • Price
  • EQ $0.41
  • MRM $1.38
  • Analyst Decision
  • EQ Buy
  • MRM
  • Analyst Count
  • EQ 3
  • MRM 0
  • Target Price
  • EQ $3.00
  • MRM N/A
  • AVG Volume (30 Days)
  • EQ 519.6K
  • MRM 21.7K
  • Earning Date
  • EQ 08-07-2025
  • MRM 05-20-2025
  • Dividend Yield
  • EQ N/A
  • MRM N/A
  • EPS Growth
  • EQ N/A
  • MRM 27.65
  • EPS
  • EQ N/A
  • MRM 0.18
  • Revenue
  • EQ $30,406,000.00
  • MRM $52,786,758.00
  • Revenue This Year
  • EQ N/A
  • MRM N/A
  • Revenue Next Year
  • EQ N/A
  • MRM N/A
  • P/E Ratio
  • EQ N/A
  • MRM $7.72
  • Revenue Growth
  • EQ N/A
  • MRM 21.55
  • 52 Week Low
  • EQ $0.27
  • MRM $0.34
  • 52 Week High
  • EQ $1.50
  • MRM $8.39
  • Technical
  • Relative Strength Index (RSI)
  • EQ 60.48
  • MRM 48.70
  • Support Level
  • EQ $0.29
  • MRM $1.33
  • Resistance Level
  • EQ $0.43
  • MRM $1.45
  • Average True Range (ATR)
  • EQ 0.06
  • MRM 0.08
  • MACD
  • EQ 0.01
  • MRM -0.01
  • Stochastic Oscillator
  • EQ 64.21
  • MRM 46.15

About EQ Equillium Inc.

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

About MRM MEDIROM Healthcare Technologies Inc.

MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.

Share on Social Networks: